363 related articles for article (PubMed ID: 35186441)
1. What's next in cancer immunotherapy? - The promise and challenges of neoantigen vaccination.
Redwood AJ; Dick IM; Creaney J; Robinson BWS
Oncoimmunology; 2022; 11(1):2038403. PubMed ID: 35186441
[TBL] [Abstract][Full Text] [Related]
2. Advances in personalized neoantigen vaccines for cancer immunotherapy.
Sun C; Xu S
Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
[TBL] [Abstract][Full Text] [Related]
3. Engineering neoantigen vaccines to improve cancer personalized immunotherapy.
Liu Z; Lv J; Dang Q; Liu L; Weng S; Wang L; Zhou Z; Kong Y; Li H; Han Y; Han X
Int J Biol Sci; 2022; 18(15):5607-5623. PubMed ID: 36263174
[TBL] [Abstract][Full Text] [Related]
4. Biomaterials-assisted construction of neoantigen vaccines for personalized cancer immunotherapy.
Wu Y; Feng L
Expert Opin Drug Deliv; 2023 Mar; 20(3):323-333. PubMed ID: 36634017
[TBL] [Abstract][Full Text] [Related]
5. Driving neoantigen-based cancer vaccines for personalized immunotherapy into clinic: A burdensome journey to promising land.
Yu G; He X; Li X; Wu Y
Biomed Pharmacother; 2022 Sep; 153():113464. PubMed ID: 36076493
[TBL] [Abstract][Full Text] [Related]
6. Tumor neoantigens: Novel strategies for application of cancer immunotherapy.
Guan H; Wu Y; Li LU; Yang Y; Qiu S; Zhao Z; Chu X; He J; Chen Z; Zhang Y; Ding H; Pan J; Pan Y
Oncol Res; 2023; 31(4):437-448. PubMed ID: 37415744
[TBL] [Abstract][Full Text] [Related]
7. Targeting Tumor Heterogeneity with Neoantigen-Based Cancer Vaccines.
Pounraj S; Chen S; Ma L; Mazzieri R; Dolcetti R; Rehm BHA
Cancer Res; 2024 Feb; 84(3):353-363. PubMed ID: 38055891
[TBL] [Abstract][Full Text] [Related]
8. Personalized neoantigen cancer vaccines: An analysis of the clinical and commercial potential of ongoing development programs.
Perrinjaquet M; Richard Schlegel C
Drug Discov Today; 2023 Nov; 28(11):103773. PubMed ID: 37730103
[TBL] [Abstract][Full Text] [Related]
9. Applications of Next-Generation Sequencing in Neoantigen Prediction and Cancer Vaccine Development.
Lancaster EM; Jablons D; Kratz JR
Genet Test Mol Biomarkers; 2020 Feb; 24(2):59-66. PubMed ID: 30907630
[TBL] [Abstract][Full Text] [Related]
10. Considerations for personalized neoantigen vaccination in Malignant glioma.
Dunn GP; Sherpa N; Manyanga J; Johanns TM
Adv Drug Deliv Rev; 2022 Jul; 186():114312. PubMed ID: 35487282
[TBL] [Abstract][Full Text] [Related]
11. Cancer neoantigen: Boosting immunotherapy.
Xu P; Luo H; Kong Y; Lai WF; Cui L; Zhu X
Biomed Pharmacother; 2020 Nov; 131():110640. PubMed ID: 32836075
[TBL] [Abstract][Full Text] [Related]
12. Personal Neoantigen Cancer Vaccines: A Road Not Fully Paved.
Fritsch EF; Burkhardt UE; Hacohen N; Wu CJ
Cancer Immunol Res; 2020 Dec; 8(12):1465-1469. PubMed ID: 33262163
[TBL] [Abstract][Full Text] [Related]
13. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
Aldous AR; Dong JZ
Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
[TBL] [Abstract][Full Text] [Related]
14. The Changing Landscape of Therapeutic Cancer Vaccines-Novel Platforms and Neoantigen Identification.
Jou J; Harrington KJ; Zocca MB; Ehrnrooth E; Cohen EEW
Clin Cancer Res; 2021 Feb; 27(3):689-703. PubMed ID: 33122346
[TBL] [Abstract][Full Text] [Related]
15. Challenges in neoantigen-directed therapeutics.
Lybaert L; Lefever S; Fant B; Smits E; De Geest B; Breckpot K; Dirix L; Feldman SA; van Criekinge W; Thielemans K; van der Burg SH; Ott PA; Bogaert C
Cancer Cell; 2023 Jan; 41(1):15-40. PubMed ID: 36368320
[TBL] [Abstract][Full Text] [Related]
16. Challenges in developing personalized neoantigen cancer vaccines.
Katsikis PD; Ishii KJ; Schliehe C
Nat Rev Immunol; 2024 Mar; 24(3):213-227. PubMed ID: 37783860
[TBL] [Abstract][Full Text] [Related]
17. Neoantigen vaccine: an emerging tumor immunotherapy.
Peng M; Mo Y; Wang Y; Wu P; Zhang Y; Xiong F; Guo C; Wu X; Li Y; Li X; Li G; Xiong W; Zeng Z
Mol Cancer; 2019 Aug; 18(1):128. PubMed ID: 31443694
[TBL] [Abstract][Full Text] [Related]
18. Personalized cancer neoantigen vaccines come of age.
Chu Y; Liu Q; Wei J; Liu B
Theranostics; 2018; 8(15):4238-4246. PubMed ID: 30128050
[TBL] [Abstract][Full Text] [Related]
19. A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment.
Chen Z; Zhang S; Han N; Jiang J; Xu Y; Ma D; Lu L; Guo X; Qiu M; Huang Q; Wang H; Mo F; Chen S; Yang L
Front Immunol; 2021; 12():691605. PubMed ID: 34484187
[TBL] [Abstract][Full Text] [Related]
20. Next generation approaches for tumor vaccination.
Patel A; Kaufman HL; Disis ML
Chin Clin Oncol; 2017 Apr; 6(2):19. PubMed ID: 28482672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]